Skip to main content

Table 4 Outcome assessment during the intervention (SPIRIT figure)

From: The effects of different doses of exercise on pancreatic β-cell function in patients with newly diagnosed type 2 diabetes: study protocol for and rationale behind the “DOSE-EX” multi-arm parallel-group randomised clinical trial

Participant timeline

Week

− 8 >

− 2

− 1

0

4

12

17

18

18

 

Domain

Visit 0

Visit 1

Visit 2

Visit 3

Visit 4

Visit 5

Visit 6

Visit 7

Visit 8

Intervention period

    

X

X

X

   

Primary outcome

 Hyperglycaemic clamp

β-cell function

  

X

    

X

 

Secondary and exploratory outcomes

 Clinical blood sampling

Clinical, functional, metabolic markers of mechanisms1

X

X

  

X

X

X

  

 Urine sampling

Systemic markers of oxidative stress2

 

X

  

X

X

X

  

 Mixed meal tolerance test

Glycaemic control during mixed meal tolerance test3

 

X

    

X

  

 Continuous glucose monitoring

24-h glucose profile

 

X

    

X

  

 Muscle and fat biopsies

Muscle and fat profiling4

  

X

    

X

 

Cardiovascular procedures

  Home blood pressure

Resting systolic and diastolic blood pressure

 

X

  

X

X

X

  

Body composition

  Magnetic resonance imaging

Visceral fat mass

   

X

    

X

  Magnetic resonance spectroscopy

Pancreatic and hepatic fat deposition

   

X

    

X

  Dual-energy X-ray absorptiometry

BW, BMI, LBM, FM

 

X

    

X

  

Physical function

  Cardiorespiratory fitness

Maximal aerobic capacity

 

X

    

X

  

  Muscular strength

1RM

 

X

    

X

  

  Physical activity behaviour

Accelerometer-based physical activity monitors

 

X

  

X

X

X

  

Patient-reported outcomes

  Mental and physical well-being

SF36 questionnaire

  

X

    

X

 

  Quality of life

SF36 questionnaire

  

X

    

X

 

  Satiety

VAS

 

X

    

X

  

  Dietary records

3-day record

  

X

 

X

X

X

  
  1. BW, body weight; BMI, body mass index; LBM, lean body mass; FM, fat mass; 1RM, one-repetition maximum; VAS, visual analogue scale
  2. 1. Total cholesterol, low- and high-density lipoprotein, HbA1c, interferon-ɣ, interleukin 10, interleukin 8, interleukin 6, interleukin 1, tumour necrosis factor α, Advanced Glycation End-products (AGE), receptor for AGE (RAGE).
  3. 2. 8-oxoGuo and 8-oxodG
  4. 3. iAUC, tAUC of glucose, insulin, glucagon and C-peptide, circulation markers of appetite regulation and gastric emptying.
  5. 4. Muscle progenitor cell isolation, snap freeze and tissue-tek.